S-1/A: Propanc Biopharma Eyes Nasdaq Uplisting with $10.35 Million Unit Offering

Propanc Biopharma aims to raise capital and transition to the Nasdaq Capital Market through a unit offering, each unit containing a share of common stock and a warrant.

Summary

• Propanc Biopharma is planning a unit offering to raise capital and list its common stock on the Nasdaq Capital Market.
• The offering consists of 1,500,000 units, each with one share of common stock and one warrant to purchase one share of common stock.
• The estimated public offering price is between $4.00 and $6.00 per unit.
• Each warrant will have an estimated exercise price equal to $4.60-6.90 per share and will expire 5 years from the date of issuance.
• The company has applied to list its common stock on the Nasdaq Capital Market under the symbol PPCB.
• The offering is contingent upon Nasdaq approval.
• The company has granted the underwriters a 45-day over-allotment option to purchase up to 225,000 additional units.
• The company intends to use the net proceeds primarily for working capital and general corporate purposes.
• The company is currently quoted on the OTC Pink Marketplace under the symbol PPCB.
• The last reported sales price for the company's common stock as quoted on the OTC was $5.68 per share on March 27, 2025.
• The company is a development-stage healthcare company focused on developing new cancer treatments.
• The company's lead product candidate, PRP, is a variation upon our novel formulation and involves pro-enzymes, the inactive precursors of enzymes.

Sentiment

Score: 5

Explanation: The document presents a balanced view, highlighting both the potential benefits of the offering and the risks associated with investing in the company. The company's financial situation and the early stage of its lead product candidate contribute to a neutral sentiment.

Positives

• The company is seeking to uplist to the Nasdaq Capital Market, which could increase visibility and liquidity.
• The company has a lead product candidate, PRP, in development for cancer treatment.
• The company has been granted Orphan Drug Designation status from the FDA for PRP for the treatment of pancreatic cancer.

Negatives

• The offering is contingent upon Nasdaq approval.
• The company is currently quoted on the OTC Pink Marketplace, which is a less liquid market.
• The company has incurred significant losses since its inception.
• The company has concerns about its ability to continue as a going concern based on the absence of revenues, recurring losses from operations and its need for additional financing to fund all of its operations.

Risks

• The offering is contingent upon Nasdaq approval.
• The company is currently quoted on the OTC Pink Marketplace, which may have an unfavorable impact on the stock price and liquidity.
• The company has incurred significant losses since its inception and may never achieve profitability.
• The company will continue to need substantial additional funding and may be forced to delay, reduce or eliminate its product development programs or commercialization efforts if it is unable to raise capital when needed.
• The company's ability to use its net operating loss carryforwards and certain other tax attributes may be limited.
• The company is a controlled company, which may limit shareholder protections.
• The company's lead product candidate, PRP, remains in the early stages of development and may never become commercially viable.
• The company faces substantial competition in the pharmaceutical and biotechnology industries.

Future Outlook

The company expects to incur significant expenses and increasing operating losses for the foreseeable future if and as it progresses PRP into clinical trials, continues its R&D, seeks regulatory approvals, establishes or contracts for a sales and marketing infrastructure, maintains and expands its intellectual property portfolio, and adds personnel.

Industry Context

The biotechnology and pharmaceutical industries are highly competitive, with numerous companies pursuing the development of new cancer treatments. Propanc Biopharma faces competition from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide.

Related Party Transactions

• The company leases its principal executive offices from North Horizon Pty Ltd., a related party, of which Mr. Nathanielsz and his wife are owners and directors.
• An institutional investor affiliated with one of the company's directors, Josef Zelinger, has loaned the company money.
• Mr. Nathanielsz's wife, Sylvia Nathanielsz, is a non-executive, part-time employee of the company.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Employees may benefit from the company's growth and development.
• Customers (patients) may benefit from the development of new cancer treatments.
• Suppliers and creditors may benefit from the company's increased financial stability.

Next Steps

• Obtain Nasdaq approval for listing.
• Initiate clinical trials for PRP.
• Continue R&D efforts.
• Seek regulatory approvals in various jurisdictions.
• Establish or contract for a sales and marketing infrastructure.

Key Dates

Keywords

Propanc Biopharma, unit offering, Nasdaq, PRP, cancer treatment, biopharmaceutical, common stock, warrants, Orphan Drug Designation, clinical trials